Highlights

  • The stock gained nearly 7% in the latest trading session.
  • Shares remain down over 28% across the past six months.
  • Broker consensus indicates significant upside from current levels.

Neuren Pharmaceuticals Limited (ASX:NEU) advanced 6.819% to AUD 13.940 on 2 March 2026, adding AUD 0.889 during the session. Trading volume reached 397,825 shares, while the bid-offer range stood narrowly at AUD 13.930–13.940, suggesting firm positioning near closing levels.

The company’s market capitalisation is approximately AUD 1.65B.

The daily gain contrasts with recent medium-term declines, reflecting a short-term rebound within a broader corrective phase.

Performance Snapshot Across Timeframes

Over the past five days, the stock has risen 10.38%, indicating renewed buying interest in the near term. However, performance across longer periods remains negative.

Shares have declined 14.28% over the past month, 28.96% over six months, and 26.34% year to date. On a 12-month basis, the stock is up 5.45%.

The longer-term perspective highlights the company’s multi-year trajectory, with a 1,014.40% increase over five years. The recent six-month retracement therefore represents a notable pullback relative to its historical growth cycle.

Broker Consensus Points to Upside

According to EODHD/Others data as of 02 march 2026, despite recent volatility, broker sentiment remains constructive. The current consensus recommendation stands at 1.83 (BUY). The average target price is AUD 23.83, implying potential upside of approximately 70.82% from the latest traded level of AUD 13.940.

The gap between the current share price and consensus target reflects expectations tied to the company’s commercial progress and product pipeline development. Analysts cite revenue visibility from key therapies and ongoing clinical positioning as central factors underpinning forecasts.

The substantial implied upside contrasts with the stock’s recent correction, positioning it as a recovery candidate in broker models.

Volatility Within Biopharmaceutical Exposure

As a specialty pharmaceutical company, Neuren Pharmaceuticals Limited operates within a sector characterised by clinical, regulatory, and commercial milestones that can influence valuation. Share price movements often reflect shifts in expectations regarding pipeline development and revenue trajectory.

The current rally interrupts a sequence of medium-term declines but does not fully offset losses recorded over the past six months.

With a market capitalisation of AUD 1.65B and a history of significant long-term appreciation, the stock continues to display elevated sensitivity to sentiment and forward-looking projections.

Neuren Pharmaceuticals climbed 6.8% to AUD 13.940, extending a 10.38% five-day gain. Despite the rebound, shares remain down nearly 29% over six months and 26% year to date. Broker consensus remains at BUY, with an average target of AUD 23.83, implying potential upside of approximately 70.82% from current levels.

FAQs

  1. How much did Neuren Pharmaceuticals shares rise recently?
    The stock increased 6.819% in the latest session, closing at AUD 13.940.
  2. What is the broker consensus target price?
    The average target price is AUD 23.83, implying significant upside from current levels.
  3. How has the stock performed over six months?
    Shares have declined approximately 28.96% over the past six months.